Skip to content

Intravenous Acetaminophen in Craniotomy

The Opioid-Sparing and Analgesic Effects of IV Acetaminophen in Craniotomy: A Prospective, Randomized, Placebo-Controlled, Double-Blind Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01598701
Enrollment
100
Registered
2012-05-15
Start date
2012-05-02
Completion date
2016-03-30
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

Acetaminophen, Intravenous Acetaminophen, Opioid Requirement, Pain, Post-Operative Pain, Craniotomy, Post-Craniotomy Pain

Brief summary

The purpose of this study is to assess the use of intravenous Acetaminophen (OFIRMEV) as an effective adjunct therapeutic agent in patients undergoing craniotomy.

Detailed description

General anesthesia will be induced by bolus administration of propofol (1.5-2.5 mg/kg IV), and fentanyl (2-3 µg/kg IV). Neuromuscular blockade will be achieved with bolus administration of rocuronium, vecuronium, or succinylcholine. Once the endotracheal tube is secured in place, the patient will be mechanically ventilated to an end-tidal CO2 of 35 mmHg. Additional procedures will include radial arterial line placement for invasive arterial blood pressure monitoring, as well as additional large-bore peripheral IV placements, or central line placement, if indicated. Anesthesia will be maintained with desflurane, propofol, and remifentanil. Once general anesthesia has been induced, but prior to the first surgical incision, the first dose of the interventional agent will be administered. Repeat doses will be administered every 6 hours until 24 hours from the time that the patient enters the PACU, for a total of up to 6 doses. Once the patient has been positioned and prepped for surgery, the surgeon will infiltrate the scalp with bupivacaine 0.5% with epinephrine 1:200,000 (15-20 ml) before skin incision. No other opioids or agents with analgesic properties (e.g., ketorolac, dexmedetomidine, ketamine) will be administered at any time during the operation. Additional medications that will be routinely administered for this procedure include dexamethasone 8-12mg IV prior to incision, and ondansetron 4mg IV at skin closure. Anticonvulsant drugs will be administered at the surgeon's request. Emergence and extubation will occur at the completion of the case per standard guidelines. The time of remifentanil infusion discontinuation and time of extubation will be noted. If necessary, extubation may occur in the post anesthesia recovery unit (PACU); otherwise, extubation will occur in the operating room. The patient will then be taken directly to the PACU. Inability to extubate a patient within two hours of completion of surgery will result in their withdrawal from the study. Once in the PACU, immediate postoperative vital signs will be recorded, including blood pressure, heart rate, respiratory rate, oxygen saturation, and RASS score. Pain scores will be assessed using the visual analog scale (VAS) upon entering the PACU or upon extubation in PACU (0 hours), and then again at 1, 2, 4, 8, 12, 16, 20, and 24 hours post-operatively. The VAS will be a 10 cm scale on a numerical scale of 0 (no pain) to 10 (severe pain) that the patient will point to in order to indicate their current level of pain. Pain scores will be measured while the patient is at rest. Post-operative nausea will also be recorded on a 10 cm numeric rating scale (NRS) at the same time intervals, with 0 indicating no nausea and 10 indicating severe nausea. All day-time VAS and NRS measurements will be made by a research assistant. Night-time measurements will be made by the nurse on the unit. While in the PACU, the time until the patient receives their first dose of analgesic medicine will be recorded. Patients will be given a 2mg nurse-administered dose of morphine upon request or if they report a pain score of ≥4/10, and will continue to be given morphine doses based on clinical assessment by the PACU/intensive care nurse, who will be blind to patient group allocation. The nurse will objectively assess the patient's pain score at least once an hour using the VAS pain scale, and an assessment of pain ≥4/10 will warrant an additional 2mg dose of morphine. Morphine dosage requirements will be recorded for 24 hours post-operatively. If morphine requirement is greater than 10mg in a 30 minute period or the patient develops an allergic reaction, pruritus, renal insufficiency, drowsiness, nausea/vomiting, or clinically relevant reason to change medication, the PACU supervising physician or ICU physician may use their clinical discretion to change the opioid rescue medication to hydromorphone (0.3mg doses). The reason for changing medication will be reported by the physician and recorded. The morphine equivalent of hydromorphone will be estimated to be 7 times the hydromorphone dose. The PACU/ICU nurses will also record any episodes of emesis, use of rescue anti-emetic medicine, and the occurrence of any other side effects. A post-operative neurologic examination will take place in the PACU. Criteria for a neurological exam to be complete is the patient's ability to successfully lift each leg off of the bed for more than two seconds on command, and to be able to hold up two fingers on each hand on command. If these criteria are not met prior to transferring the patient from the PACU to the ICU, a post-operative neurologic complication will be considered and the patient will be withdrawn from the study. The time until the patient is ready to be discharged from the PACU will also be noted. Patients with a modified Aldrete score of ≥ 8 (see Appendix 1) will be considered ready for discharge. These criteria will be assessed by either the research assistant or PACU staff. At the end of the 24 hour post-operative time period, a patient interview will be conducted. At this interview the patient will asked about their subjective satisfaction with their analgesic protocol, as well as any adverse effects they may have noticed. The 24 hour morphine consumption will also be recorded at this time. After the study is completed, patients may receive IV or oral acetaminophen therapy at the discretion of the primary physician.

Interventions

DRUGAcetaminophen

Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.

DRUGPlacebo

100 mL 0.9% Sodium Chloride

Sponsors

Mallinckrodt
CollaboratorINDUSTRY
The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No

Inclusion criteria

* Adults * Undergoing Craniotomy for Supratentorial Tumor Resection * Weight between 50 and 120 kilograms * ASA Physical Status I-III * Be able to communicate verbally * Be able to use Visual Analog Score

Exclusion criteria

* Allergies to acetaminophen, morphine or any of the anesthetic agents required by the protocol. * Use of opioids, tramadol, benzodiazepines, or gabapentin on a daily basis for \> 7 days prior to the day of surgery. * Use of acetaminophen, NSAIDs, or any other analgesic medication in the 12 hours immediately prior to study enrollment. * Hepatic insufficiency (elevated transaminases \> 1.5 times the upper limit of normal) or renal insufficiency (plasma creatinine \> 2mg/dl). * Known or suspected history of alcohol or illicit drug abuse. * Pregnant or breast-feeding. * Surgical plan for infratentorial (suboccipital) craniotomy. * Plan for neurophysiologic monitoring that precludes the use of neuromuscular blockade. * Inability to communicate due to a language barrier, impaired consciousness, cognitive defect or intellectual disability. * Uncontrolled Hypertension

Design outcomes

Primary

MeasureTime frameDescription
Post-Operative Opioid Requirement24 hours post-operativelyOpioid Consumption will be monitored in the first 24 post-operative hours. All non-opioid analgesics are disallowed. Total opioid consumption was calculated based on morphine equivalents (MEs), where 1 mg of IV morphine was equivalent to 1 ME, and 1 mg IV hydromorphone was calculated as 7 MEs.

Secondary

MeasureTime frameDescription
Post-Operative Pain24 Hours Post-OperativelyPatients will be assessed for pain using a Visual Analogue Scale (VAS) Scale at set time points after surgery (0,1,2,4,8,12,16,20,24 hours post-operatively). The Visual Analogue Scale (VAS) scale was measured on a scale of 0 - 10 (0 = no pain, 1-3 = mild, 4-6 = moderate, 7-10 = severe). Higher values on the VAS represent a worse outcome. The two rows below report: 1. the average VAS score for the least amount of pain reported per group and 2. the average VAS score of the worst amount of pain reported per group.
Post-Operative Side Effects24 Hours Post-OperativelyPatients will be monitored for 24 hours post-operatively to detect the incidence of any drug or opioid-related side effects. These side effects were not considered to be adverse events.
Time to Extubation at Emergence From AnesthesiaTime from of discontinuation of anesthetic to time of extubation, an average of 7 minutes
Time for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge CriteriaFrom time of entry to PACU to time to meet PACU discharge criteria, an average of 12 minutes

Countries

United States

Participant flow

Participants by arm

ArmCount
Intravenous Acetaminophen
Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes. Acetaminophen: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
50
Placebo
Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen. Placebo: 100 mL 0.9% Sodium Chloride
50
Total100

Baseline characteristics

CharacteristicIntravenous AcetaminophenPlaceboTotal
Age, Continuous50.0 years
STANDARD_DEVIATION 16.3
51.5 years
STANDARD_DEVIATION 14.4
50.75 years
STANDARD_DEVIATION 15.35
Sex: Female, Male
Female
24 Participants31 Participants55 Participants
Sex: Female, Male
Male
26 Participants19 Participants45 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 501 / 50
serious
Total, serious adverse events
0 / 500 / 50

Outcome results

Primary

Post-Operative Opioid Requirement

Opioid Consumption will be monitored in the first 24 post-operative hours. All non-opioid analgesics are disallowed. Total opioid consumption was calculated based on morphine equivalents (MEs), where 1 mg of IV morphine was equivalent to 1 ME, and 1 mg IV hydromorphone was calculated as 7 MEs.

Time frame: 24 hours post-operatively

ArmMeasureValue (MEDIAN)
Intravenous AcetaminophenPost-Operative Opioid Requirement11.0 Morphine Equivalents
PlaceboPost-Operative Opioid Requirement10.1 Morphine Equivalents
Secondary

Post-Operative Pain

Patients will be assessed for pain using a Visual Analogue Scale (VAS) Scale at set time points after surgery (0,1,2,4,8,12,16,20,24 hours post-operatively). The Visual Analogue Scale (VAS) scale was measured on a scale of 0 - 10 (0 = no pain, 1-3 = mild, 4-6 = moderate, 7-10 = severe). Higher values on the VAS represent a worse outcome. The two rows below report: 1. the average VAS score for the least amount of pain reported per group and 2. the average VAS score of the worst amount of pain reported per group.

Time frame: 24 Hours Post-Operatively

ArmMeasureGroupValue (MEAN)Dispersion
Intravenous AcetaminophenPost-Operative PainLeast amount of pain reported1.4 units on a scaleStandard Deviation 1.8
Intravenous AcetaminophenPost-Operative PainWorst amount of pain reported6.3 units on a scaleStandard Deviation 2.5
PlaceboPost-Operative PainLeast amount of pain reported2.6 units on a scaleStandard Deviation 2.7
PlaceboPost-Operative PainWorst amount of pain reported6.4 units on a scaleStandard Deviation 3.2
Secondary

Post-Operative Side Effects

Patients will be monitored for 24 hours post-operatively to detect the incidence of any drug or opioid-related side effects. These side effects were not considered to be adverse events.

Time frame: 24 Hours Post-Operatively

Population: The # analyzed does not match the # who completed or the overall # analyzed because data on all side effects was not collected for all participants who completed, either due to lack of collection of data by research/nursing staff (for emesis) or due to lack of reporting by participants on a questionnaire(for itching, dizziness, and drowsiness).

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Intravenous AcetaminophenPost-Operative Side EffectsDrowsiness24 Participants
Intravenous AcetaminophenPost-Operative Side EffectsItching8 Participants
Intravenous AcetaminophenPost-Operative Side EffectsEmesis23 Participants
Intravenous AcetaminophenPost-Operative Side EffectsDizziness14 Participants
PlaceboPost-Operative Side EffectsEmesis20 Participants
PlaceboPost-Operative Side EffectsDrowsiness19 Participants
PlaceboPost-Operative Side EffectsDizziness14 Participants
PlaceboPost-Operative Side EffectsItching5 Participants
Secondary

Time for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria

Time frame: From time of entry to PACU to time to meet PACU discharge criteria, an average of 12 minutes

Population: The number analyzed is greater than the number completed because this data was collected for more patients than completed the study, and all data that was collected is reported here.

ArmMeasureValue (MEAN)Dispersion
Intravenous AcetaminophenTime for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria11.4 minutesStandard Deviation 7.2
PlaceboTime for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria13.5 minutesStandard Deviation 8.4
Secondary

Time to Extubation at Emergence From Anesthesia

Time frame: Time from of discontinuation of anesthetic to time of extubation, an average of 7 minutes

Population: The number analyzed is greater than the number completed because this data was collected for more patients than completed the study, and all data that was collected is reported here.

ArmMeasureValue (MEDIAN)
Intravenous AcetaminophenTime to Extubation at Emergence From Anesthesia6 minutes
PlaceboTime to Extubation at Emergence From Anesthesia8 minutes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026